The coronavirus pandemic has impacted us all and in ways that were impossible to predict just a few months ago. Across the healthcare sector we are seeing an unprecedented response in communication, collaboration, speed and agility, as we unite in a common purpose to fight the COVID-19 pandemic.
No-one is clear when we will come out of the other side and what will be the longer-term impact on how we work and do business. And of course, the key question is how it will impact investments in the biotech & medtech sector .
The Optimum Strategic Communications Annual Healthcare Investor Conference in partnership with Dechert LLP will take place on Thursday 8th October 2020.
The conference now in its 12th year, features leading speakers from the healthcare and investment communities each providing insights on the latest trends, developments and impacts on the industry.
The audience consists of senior management from private and public companies across Europe’s healthcare and life-sciences sector, as well as a number of investors and analysts from the investment community.
For more information please follow the link to the Press release .
Reviews from our past speakers on what makes Optimum's Healthcare Investor Conference unique.
Leading speakers from the healthcare and investment communities providing insights on the latest trends and impacts on the industry.
A selection of some of our brilliant panellists from previous years.
Kasim Kutay Novo Holdings
Werner Lanthaler Evotec
Anne Marden JP Morgan Asset Management
Jan van de Winkel Genmab
Geraldine O'Keeffe LSP
Kieran Murphy GE Healthcare
Antoine Papiernik Sofinnova Partners
Clive Cookson Financial Times
Oliver Maier Bayer
Dan Mahony Polar Capital
Martin Murphy Syncona
Linden Thomson AXA Investment Managers
Edwin Moses NED Various
Annalisa Jenkins NED Various
Paul Major Bellevue Asset Management
Professor Tony Young OBE NHS England
Roel Bulthuis INKEF Capital
David Pinniger Polar Capital
Vicky Darbyshire JP Morgan Asset Management
Hakan Goker M Ventures
George Freeman Government adviser on Life Sciences
Catherine Pickering iOnctura
Gavin MacGregor HBM Partners
Mike Ward Informa Group
Andrew Holder Mole Valley Asset Management
Richard Girling Centreview Partners
Justin Stebbing Imperial College London
Deborah Harland SR One
Lisa Urquhart Vantage
Thomas Burt Sofinnova
Harry Destecroix Unit DX
Ilan Chaitowitz Nomura Asset Management
Dale Raine Lazard
Jonathan Tobin Arix Bioscience
Soren Moller Novo Holdings
Jasper Bos M Ventures
Marc Booty Pictet Asset Management
Eva Haas Optimum Strategic Communications
Ian Nicholson F2G
Anker Lundemose Mission Therapeutics
Sam Fazeli Bloomberg Intelligence
Professor Sir Michael Rawlins NICE
Andy Richards CBE NED Various
Mary Clark Optimum Strategic Communications
Optimum Strategic Communications in partnership with Dechert
Optimum Strategic Communications is an international strategic healthcare communications firm which specialises in investor relations, corporate and financial communications. Our senior team of healthcare specialists are experienced and trusted advisors to some of the world’s most exciting public and private companies, both large and small, across pharmaceuticals, medtech, biotech, health tech and healthcare services.
Over the last 20 years we have worked with over 200 healthcare companies, advising them on financial communications and investor relations, including major corporate activity such as fundraising, IPOs, and M&A, as well as corporate reputation and crisis scenarios. We have advised on numerous cross border transactions and have supported IPOs on the London Stock Exchange, Euronext and NASDAQ.
We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last two decades. Our team includes ex-fund managers and equity analysts, scientists and financial and corporate communications specialists. www.optimumcomms.com
Dechert’s Life Sciences and Healthcare group provides global support to Life Sciences and Healthcare industry participants and investors, assisting them to navigate the interplay of business, legal, and regulatory issues. For further information click here.
The half day event will kick off at 11:30 with fireside chats and panel discussions throughout the afternoon. We will finish with virtual networking until 7pm.
All times listed are in GMT.
Mary Clark, Managing Director, Optimum Strategic Communications
Robert Darwin, Partner, Dechert LLP
Chair: Dan Mahony, Co-head of Healthcare, Polar Capital
Kieran Murphy, President & CEO, GE Healthcare
Chair: Mike Ward, Head of Thought Leadership, Decision Resources Group, part of Clarivate
Philippe Lopes-Fernandes Executive Vice President, Chief Business Officer, Ipsen
Peter Stein, Chief Executive Officer, Norgine Group
Chair: Mary Clark, Managing Director, Optimum Strategic Communications
Oliver Maier, Head of IR, Bayer
Kevin Mannix, Senior VP & Head of IR, Teva Pharmaceutical
Chair: Clive Cookson, Science Editor, Financial Times
Sean Marett, Chief Business and Chief Commercial Officer, BioNTech
Professor James Logan, Head of Department of Disease Control, London School of Hygiene and Tropical Medicine
Kate Bingham, Chair of UK Vaccine Taskforce & Managing Partner of SV Health Investors
Rajeev Venkayya, MD President Global Vaccine Business Unit, Takeda Pharmaceuticals
Chair: Robert Darwin, Partner, Dechert LLP
Isabella Eichler, Director, Altor Equity Partners
Linden Thomson, Fund Manager, AXA Investment Managers
Guillaume Vignon, Senior Vice President Business Development, BeiGene
Stavros Mercouris, Director, KKR
Elisa Petris, Partner, Syncona
We look forward to welcoming you to our first virtual conference.
This year’s conference will be run as a virtual event. Joining instructions will be sent to confirmed attendees the week prior to the event.
